Synergistic strategies by combining nanoreactors and prodrugs hold tremendous potential in anticancer treatment. However, precise death of target cancer cells remains a significant challenge due to the absence of an elaborate cancer targeting strategy. Here, a dual‐targeting approach that combines the action of H2O2‐producing folate receptor‐targeted nanoreactors with a cyclooxygenase‐2 (COX‐2) targeted prodrug is reported. A folate‐modified silica nanoreactor encapsulating glucose oxidase (GOX) is prepared to generate H2O2, which induces oxidative stress and allows the activation of the prodrug by targeted intracellular delivery. A novel prodrug bearing both COX‐2 targeting Celecoxib and SN‐38 anticancer agent with an H2O2‐cleavable thioketal linker to activate the drug is presented. By dual‐targeting, the generated H2O2 from GOX triggers the cleavage of a thioketal linker in the prodrug to produce the active form of the SN‐38 anticancer drug in cancer cells inducing synergistic cell death. This dual‐targeting strategy with a synergistic potency can aid in developing selective and effective anticancer therapeutics.
Yoo Jin Choi, Yoonhyeong Byun, Jae Seung Kang, Hyeong Seok Kim, Youngmin Han, Hongbeom Kim, Wooil Kwon, Do-Youn Oh, Woo Hyun Paik, Sang Hyub Lee, Ji Kon Ryu, Yong-Tae Kim, Kyungbun Lee, Haeryoung Kim, Eui Kyu Chie, and Jin-Young Jang. Gut and Liver 2021;15:466-75. https://doi.org/10.5009/gnl20070
1 January 2021 in Annals of Surgical Treatment and Research
Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been proposed as useful preoperative biomarkers of extrahepatic bile duct cancer (EBDC). This study investigated the accuracy of CEA and CA19-9 for preoperative diagnosis of EBDC. Patients who underwent surgery for EBDC at a tertiary centre between 1995 and 2018 were studied, and those with concurrent hepatobiliary diseases (including gallbladder cancer, intraductal papillary mucinous neoplasms of pancreas), which could affect CEA or CA19-9 levels, were excluded. The control group included patients who underwent cholecystectomy for benign gallbladder diseases during the same period. Diagnostic accuracy was determined using sensitivity, specificity and area under the receiver operating characteristic curve (AUC). After excluding 23 patients, 687 patients (488 men and 199 women, mean age 65.8 years) were compared with the control group of 2310 patients. Median CEA and CA19-9 levels were 1.8 μg/l and 47.0 kU/l in patients with EBDC. CEA (cut-off 5.0 μg/l) showed AUC of 0.541, sensitivity 9.0 per cent and specificity 99.2 per cent, whereas CA19-9 (cut-off 37.0 kU/l) showed AUC of 0.753, sensitivity 56.2 per cent and specificity 94.5 per cent. Sensitivity of CA19-9 was lower in early (T stages 0–II) than advanced (T stages III and IV) cancer (47.0 versus 64.9 per cent), and also lower in N0 stage cancer than lymph node metastasis (50.1 versus 68.8 per cent). Serum CEA and CA19-9 showed low sensitivity limiting their usefulness as diagnostic biomarkers of EBDC.
22 October 2021 in The International Journal of Medical Robotics and Computer Assisted Surgery